Experimental drug CS18 shows promise in overcoming cancer drug resistance

A new experimental compound, designated CS18, has shown promise in overcoming cancer drug resistance by targeting multiple survival mechanisms employed by tumors. Researchers reported that the agent enhances the efficacy of standard treatments and re‑sensitizes lung cancer cells that had become unresponsive to existing therapies.

In preclinical studies, CS18 restored drug sensitivity in resistant lung cancer cell lines and slowed tumor progression in animal models, indicating its potential to augment current therapeutic regimens. The findings suggest that further investigation of CS18 could lead to new strategies for managing drug‑resistant cancers.